In a report released today, Boobalan Pachaiyappan from H.C. Wainwright reiterated a Buy rating on Entrada Therapeutics Inc (TRDA – Research Report), with a price target of $25.00. The company’s shares closed yesterday at $13.32.
According to TipRanks, Pachaiyappan is a 3-star analyst with an average return of 9.0% and a 50.00% success rate. Pachaiyappan covers the Healthcare sector, focusing on stocks such as Galecto, Entrada Therapeutics Inc, and Gain Therapeutics.
Entrada Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $25.00.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $24.38 and a one-year low of $5.59. Currently, Entrada Therapeutics Inc has an average volume of 46.73K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Entrada Therapeutics Inc mission is to transform the treatment of devastating diseases and improve patients quality of life by developing intracellular biologics. Leveraging its proprietary Endosomal Escape Vehicle platform, Entrada is creating a diverse and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to efficiently target and engage underlying drivers of diseases.
Read More on TRDA:
- Entrada Therapeutics Reports First Quarter 2023 Financial Results
- Entrada Therapeutics appoints Zeiher to board of directors
- Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors
- Entrada Therapeutics initiated with a Buy at H.C. Wainwright
- Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference
